Aquestive offloads film formulation seizure drug

This Week

Nov 2, 2022

Lilly pumps $50M into Purdue pact to study intrathecal and nanoparticle drug delivery

VacV exits stealth with systemic oncolytic viral delivery tech and vision of immune system stimulation

Aquestive offloads film formulation seizure drug to Assertio, securing cash for epinephrine R&D

Nanoparticles maximize cancer drug's STING in preclinical tests

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

Lilly pumps $50M into Purdue pact to study intrathecal and nanoparticle drug delivery

By Nick Paul Taylor

Eli Lilly is plowing a further $50 million into its research collaboration with Purdue University, signing up to work with its partner for another five years on challenges including intrathecal and nanoparticle drug delivery.
 

Top Stories

VacV exits stealth with systemic oncolytic viral delivery tech and vision of immune system stimulation

By Nick Paul Taylor

VacV Biotherapeutics has taken early steps toward the validation of its systemically deliverable Vaccinia virus, exiting stealth with $3 million to complete preclinical studies of its cancer immunotherapies.

Aquestive offloads film formulation seizure drug to Assertio, securing cash for epinephrine R&D

By Nick Paul Taylor

Specialty pharma company Assertio Holdings has expanded its portfolio through a deal with Aquestive Therapeutics, paying $9 million upfront for exclusive rights to the Sympazan oral film formulation.

Nanoparticles maximize cancer drug's STING in preclinical tests

By Nick Paul Taylor

Researchers have turned to drug delivery nanoparticles to maximize the anti-cancer STING of a molecule, pointing to a possible way to unlock the potential of a pathway that has caught the eye of the industry.

Gilead hits surprise FDA rejection for hepatitis D drug already authorized in Europe for 2 years

By Kevin Dunleavy

Nearly two years after shelling out $1.4 billion for MYR and its hepatitis D drug , Gilead has yet to gain sanction for bulevirtide in the U.S., and it’s not happening any time soon as the FDA has given it a thumbs down.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Biogen's earnings call, AstraZeneca's CTLA-4 nod

This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years.

'The Top Line': Pfizer's kickback lawsuit, top vaccine companies

'Podnosis': Medicare Advantage, Health Payer summit highlights

 

Resources

Webinar

Launch Success: Why take the risk? Join our live webinar

‘The Launch Rollercoaster: Riding the Highs and Lows’ webinar will include insights and strategies from HCPs and cross-functional launch experts. Grab your virtual seat to learn about the common challenges and tap into actionable learnings to drive launch success.

Presented by: Lumanity | Thursday, November 15, 2022 2.00 PM GMT / 9.00 AM EST

Whitepaper

EHR vs Registry Data for RWE – Heart Failure as a Case Study

Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs?

Sponsored by: Veradigm Health

eBook

The Essential Components of a Successful Remote Patient Monitoring Program

Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs.

Sponsored by: Health Catalyst

Whitepaper

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Sponsored by: Catalent

Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Sponsored by: Catalent

Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Sponsored by: Catalent

Webinar

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Sponsored by: Catalent Biologics

Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Sponsored by: Catalent Biologics

Whitepaper

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Sponsored by: Catalent

Whitepaper

Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Sponsored by: Catalent

 

Upcoming Fierce Events

2-3
Nov
Pharma Meeting Professionals Summit
Atlantic City, NJ
2
Nov
Fierce Biotech Cell & Gene Forum
Free Virtual Event
14-16
Nov
European Trial Master File Summit
London, UK
15-16
Nov
Fierce Diversity, Equity & Inclusion Forum
Free Virtual Event
30-1
Nov-Dec
Launch Readiness for Medical Affairs & Communications Teams
Virtual Event

View all events